JP2010519279A - 口腔乾燥症またはドライマウスの治療用組成物 - Google Patents
口腔乾燥症またはドライマウスの治療用組成物 Download PDFInfo
- Publication number
- JP2010519279A JP2010519279A JP2009550731A JP2009550731A JP2010519279A JP 2010519279 A JP2010519279 A JP 2010519279A JP 2009550731 A JP2009550731 A JP 2009550731A JP 2009550731 A JP2009550731 A JP 2009550731A JP 2010519279 A JP2010519279 A JP 2010519279A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- xerostomia
- olive oil
- weight
- xylitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 206010013781 dry mouth Diseases 0.000 title claims abstract description 87
- 208000005946 Xerostomia Diseases 0.000 title claims abstract description 59
- 238000011282 treatment Methods 0.000 title description 19
- 239000004006 olive oil Substances 0.000 claims abstract description 41
- 235000008390 olive oil Nutrition 0.000 claims abstract description 41
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 29
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 28
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000811 xylitol Substances 0.000 claims abstract description 28
- 235000010447 xylitol Nutrition 0.000 claims abstract description 28
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 28
- 229960002675 xylitol Drugs 0.000 claims abstract description 28
- 239000000120 Artificial Saliva Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000002324 mouth wash Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- -1 abrasive Substances 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000000606 toothpaste Substances 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 210000003254 palate Anatomy 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 229940034610 toothpaste Drugs 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 229940112822 chewing gum Drugs 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000000395 remineralizing effect Effects 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 210000004268 dentin Anatomy 0.000 abstract description 37
- 230000028327 secretion Effects 0.000 abstract description 34
- 208000024891 symptom Diseases 0.000 abstract description 19
- 238000005115 demineralization Methods 0.000 abstract description 13
- 230000002328 demineralizing effect Effects 0.000 abstract description 13
- 230000000638 stimulation Effects 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000002378 acidificating effect Effects 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 3
- 210000003296 saliva Anatomy 0.000 description 52
- 238000012360 testing method Methods 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000005259 measurement Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 210000003298 dental enamel Anatomy 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 208000002925 dental caries Diseases 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 229940051866 mouthwash Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000002390 adhesive tape Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 210000003079 salivary gland Anatomy 0.000 description 5
- 239000000021 stimulant Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000004283 incisor Anatomy 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 240000004307 Citrus medica Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000008617 Tooth Demineralization Diseases 0.000 description 2
- 206010072665 Tooth demineralisation Diseases 0.000 description 2
- 241000364021 Tulsa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960003403 betaine hydrochloride Drugs 0.000 description 2
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229940091249 fluoride supplement Drugs 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000001847 jaw Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- VUOLWBPDWWANLX-FJXQXJEOSA-M potassium 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound [K+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O VUOLWBPDWWANLX-FJXQXJEOSA-M 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- LRHDEXKRLAKMOP-UHFFFAOYSA-N 3-[3-aminopropyl(2-hydroxyethyl)amino]-3-heptadecylpentane-1,5-diol;dihydrofluoride Chemical compound F.F.CCCCCCCCCCCCCCCCCC(CCO)(CCO)N(CCO)CCCN LRHDEXKRLAKMOP-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- FFDVZARSBRNLFY-UHFFFAOYSA-N 4,5-dihydro-3h-pyrazol-3-ylurea Chemical compound NC(=O)NC1CCN=N1 FFDVZARSBRNLFY-UHFFFAOYSA-N 0.000 description 1
- UMGBMSLNJZIMQY-UHFFFAOYSA-N 4,5-dihydroimidazol-1-ylurea Chemical compound NC(=O)NN1CCN=C1 UMGBMSLNJZIMQY-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000001938 Citrus medica Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024552 Lip dry Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028111 Mucosal dryness Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- KMXTYZBQPJXGNK-UHFFFAOYSA-N hexadecan-1-amine;hydron;fluoride Chemical compound F.CCCCCCCCCCCCCCCCN KMXTYZBQPJXGNK-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003476 methylparaben sodium Drugs 0.000 description 1
- 210000000258 minor salivary gland Anatomy 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- 229960001245 olaflur Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000001885 petroselinum crispum mill. leaf oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000007406 plaque accumulation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960005359 propylparaben sodium Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000008655 root caries Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、口腔障害の治療の分野に関する。具体的には、本発明は、口腔乾燥症およびその関連問題の治療用組成物に関する。
唾液は自然体液であり、この機能は口腔咽頭、消化器、および全身の健康にとって極めて重要である。唾液機能は一見単純である。しかしながら、その組成の複雑さはその多数の性質を反映している。唾液の量または質が低下すると、複数の問題が起こり、口腔乾燥症または「ドライマウス」もしくは「口腔灼熱」と呼ばれる。
1.口を乾燥させる薬物の消費:500を超える薬物群に副作用として口腔乾燥症があり、患者への投薬中止の主な理由の一つはこれが原因である。これらは口腔乾燥症の最多数の症例に関与する。長期処置後、薬物の中止にもかかわらず、唾液欠乏症は通常長く続く。
この影響を最も高い頻度でもたらす薬物は、利尿薬(ヒドロクロロチアジド、アミロライド)、鎮静薬、抗鬱薬(セロトニン再取り込み阻害薬およびとりわけ三環系抗鬱薬)、抗高血圧薬、抗炎症薬、鬱血除去薬(フェニルプロパノールアミン、プソイドエフェドリン)、抗不安薬(ジアゼパム)、抗コリン作動性の鎮痙剤(アトロピン、オキシブチニン)、止瀉薬(ロペラミド、ジフェノキシレート)、抗ヒスタミン薬(クロルフェナミン、ロラタジン)、非ステロイド抗炎症薬(ピロキシカム、イブプロフェン)、オピオイド鎮痛薬(モルヒネ)、筋弛緩薬(バクロフェン)、気管支拡張薬(イプラトロピウム、サルブタモール)、抗パーキンソン薬(レボドパ、ビペリデン)、抗にきび薬(イソトレチノイン)並びにフェノチアジンおよびブチロフェノンなどの抗精神病薬である。
2.頭頸部放射線療法(最も広く認識されている原因の一つ)などの腫瘍学的処置。さらに、かつより頻繁には、腫瘍学的化学療法も。さらには甲状腺癌における放射性ヨード療法も。
3.自己免疫疾患:自己免疫疾患によって唾液の分泌が永久的に減少される。シェーグレン症候群、全身性紅斑性狼瘡、関節リウマチ、多発性筋炎/皮膚筋炎、および強皮症を強調することができる。
4.感染症:HIV、肝炎。
5.免疫抑制療法を受けた移植患者:唾液腺機能低下。
6.透析患者。
7.糖尿病、関節炎、アルツハイマー病、および老年性認知症などの全身性疾患。
8.不安、鬱病、および神経性食欲不振症などの精神疾患。
9.アルコール、タバコ、および薬物などの常習性薬物の消費。我々の時代における共通因子。
唾液分泌減退および口腔乾燥症の症状に苦しんでいる成人集団における本発明の組成物の効力
材料および方法
被験者
50歳〜67歳の一般集団から合計40名の参加者を募集し、登録した。
被験者の全員が薬物乱用によるドライマウス症状の経歴を報告した。被験者は全員が次の基準に適合した:
中性pHに処方した三つの有効成分(オリーブ油、トリメチルグリシン、およびキシリトール)を含む局所用ドライマウス製品を用いた。
具体的には、試験製品を四つの異なる型:練り歯磨き、口内洗浄剤、スプレー、およびゲルにより処方した。
総ての患者には、標準口腔組織検査を実施すると同時に、従前に記載されているプロトコール(Navazesh, 前掲)に従って非刺激時の唾液の分泌を測定することにある一連の基準測定を行った。
標準口腔組織検査を実施すると同時に、従前に記載されているプロトコール(Navazesh, 前掲)に従って非刺激時の全唾液を採取した。
ドライマウスの八つの側面に焦点を合わせた有効な口腔乾燥症VAS(視覚的アナログスケール(Visual Analogue Scale))質問票を使用した(Pai S, et al. "Development of a Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunction", Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, & Endodontics, 2001;91(3):311-6)。100mmの水平線上にマークをつけて、被験者が受けた乾燥レベルを示すように被験者に依頼した。質問票に含まれる側面のうちの二つの側面(No.2およびNo.3)は唾液腺機能低下と関連している(Fox et al. "Subjective reports of xerostomia and objective measures of salivary gland performance", Journal of the American Dental Association, 1987;115(4):581-4)。前記側面のうちの三つの側面(No.6、No.7、およびNo.8)は、ドライマウス研究に既に用いられており(Foxら前掲; Narhi T O. "Prevalence of subjective feelings of dry mouth in the elderly", Journal of Dental Research, 1994;73(1):20-5)、口唇の乾燥(No.6)によって唾液腺機能低下の予測に成功した(Navazesh M, et al., "Clinical criteria for the diagnosis of salivary gland hypofunction", Journal of Dental Research, 1992;71(7):1363-9)。前記側面は以下に記載される:
本研究に用いた口腔乾燥症に関連する生活の質についての質問票は、有効な形式(Henson B S et al., "Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy", Oral Oncology, 2001;37(1):84-93)から抽出した12項目の質問を含む。この質問票は、ドライマウスが人の生活の質にどのように影響を及ぼすのかを解析することを目的としている。これらの質問は3群に分類される:身体機能、個人機能、および疼痛。含めた質問は以下に記載される:
本研究の構成に40名の被験者を選抜し、そのうちの39名が訪問の総てを終了した。
図1は、通常のドライマウス用製品(対照)および本発明の組成物(試験)の局所適用の開始時および1週間後の非刺激時の唾液の分泌値を示す。群間の差異、約180%は、p=0.03であり、統計的に有意である。
図2は、通常のドライマウス用製品(対照)および本発明の組成物(試験)の局所適用の1週間後の口腔乾燥症VAS質問票の結果による症状の変化を示す。正の変化は症状の減少を意味し、負の変化は症状の増加を意味し、はっきりしない変化は変化がないことを意味する。8項目の質問群に関して、群間の差は統計的に有意である(p=0.011)。
図3は、通常のドライマウス用製品(対照製品)および本発明の組成物(試験製品)の使用後に口腔乾燥症に関連する生活の質において検出された変化を示す。被験者の生活の質は、その変化値が小さいほど高いことになる。群間に有意差が認められた:身体機能(p=0.03)、個人機能(p=0.03)、および疼痛(p=0.01)。
本発明の組成物の歯脱灰に対する保護能力についての、オリーブ油のその能力との比較
極端な腐食条件にさらしたエナメル質および象牙質において、オリーブ油、トリメチルグリシン、およびキシリトールを用いて処方した口内洗浄剤の保護能力を、オリーブ油のものと比較して、分析した。効果の評価のため、蒸留水からなる対照を含めた。
サンプル調製
ウシ顎から抜き取った切歯を使用し、それらの切歯を室温で0.5%チモール溶液中に浸漬した。それらの歯をセメント質−エナメル質接合部で水冷式ダイヤモンドメス(Exakt, Norderstedt, Germany)を用いて切断し、歯冠と歯根をアクリル樹脂製シリンダー(Paladur, Heraeus Kulzer, Wehrheim, Germany)内に埋め込んだ。歯根セメント質を完全に除去した。次いで、エナメル質および象牙質の表面を研磨して、エナメル質および象牙質の最外層の厚さをおよそ200μmまで減少させ、マイクロメーター(Digimatic(登録商標), Micrometer, Mitutoyo, Tokyo, Japan)を用いてこれを制御した。
エナメル質および象牙質の試験片を10サイクルの前処理、再石灰化、脱灰、および再石灰化に供した。前処理は、各試験片を次の調製物のうちの1調製物中に5分間浸漬することにあった:(A)蒸留水、(B)オリーブ油、トリメチルグリシン、およびキシリトールを含む口内洗浄剤、および(C)オリーブ油。
プロファイルまたは形状測定を行い(Mahr Perthometer, Gottingen, Germany)、エナメル質および象牙質の喪失を定量した。試験前に、基準測定を行った(この基準測定値は、試験後にエナメル質および象牙質の喪失を算出するための参照として用いる表面の評価に役立てた)。この目的を達成するために、各試験片の中央に1000μm間隔で六つのマークをつけた。プロファイル測定の長さは250μmの間で実行し、0.69μmごとにデータ収集を行う。試験後、粘着テープを外し、サンプルをもう一度分析した。このようにして、腐食表面の平均深度を特定のソフトウェア(Mahr Perthometer Concept 7.0, Mahr, Gottingen, Germany)を用いて基準表面プロファイルに対して算出した。
エナメル質および象牙質の喪失を各群について算出し(平均±標準偏差)、スチューデントt検定、続いて多重比較のボンフェロ−ニt検定によって統計的に解析した(Statistica 6.0, Statsoft, Tulsa, USA)。
3群における象牙質喪失の平均値を図4に示す。
対照群(A)における象牙質喪失は9.6μm±1.0であった。オリーブ油(B)を用いて得られた結果からは、蒸留水に対する差は示されていない(9.21μm±1.5)。試験溶液(C)は、水およびオリーブ油に対して改善を示す(7.41μm±0.9)が、その改善は水に対してのみ有意である。
3群におけるエナメル質喪失の平均値を図5に示す。
対照群(A)における象牙質喪失(Dentin loss)は26.7μm±1.3であった。オリーブ油(B)を用いて得られた結果からは、蒸留水に対する差は示されていない(28.7μm±1.8)。試験溶液(C)は、水およびオリーブ油に対して有意な改善を示す(21.2μm±1.1)。
本発明の組成物の歯脱灰に対する保護能力についての、本発明の組成物の三成分単独でのその能力との比較
極端な腐食条件にさらした象牙質において、オリーブ油、トリメチルグリシン、およびキシリトールを用いて処方した口内洗浄剤の保護能力を、試験する口内洗浄剤に用いた同じ濃度の三成分単独での水溶液のものと比較し、分析した。効果の評価のため、蒸留水からなる対照を含めた。
サンプル調製
ウシ顎から抜き取った切歯を使用し、それらの切歯を室温で0.5%チモール溶液中に浸漬した。それらの歯をセメント質−エナメル質接合部で水冷式ダイヤモンドメス(Exakt, Norderstedt, Germany)を用いて切断し、歯冠と歯根をアクリル樹脂製シリンダー(Paladur, Heraeus Kulzer, Wehrheim, Germany)内に埋め込んだ。歯根セメント質を完全に除去した。次いで、象牙質の表面を研磨して、象牙質の最外層の厚さをおよそ200μmまで減少させ、マイクロメーター(Digimatic(登録商標), Micrometer, Mitutoyo, Tokyo, Japan)を用いてこれを制御した。
象牙質の試験片を10サイクルの前処理、再石灰化、脱灰、および再石灰化に供した。前処理は、各試験片を次の調製物のうちの1調製物中に5分間浸漬することにあった:(A)蒸留水、(B)オリーブ油、トリメチルグリシン、およびキシリトールを含む口内洗浄剤、(C)2%オリーブ油水中エマルジョン、(D)2%トリメチルグリシン水溶液、および(E)1%キシリトール水溶液。溶液C、D、およびEは、試験する口内洗浄剤Bの成分構成と同じ割合で調製する。2%オリーブ油水中エマルジョンは各処置の前に高速ミキサーを用いて調製し、微細分散したエマルジョンを得た。
プロファイルまたは形状測定を行って(Mahr Perthometer, Gottingen, Germany)、象牙質喪失を定量した。試験前に、基準測定を行った(この基準測定値は、試験後に象牙質の喪失を算出するための参照として用いる表面の評価に役立てた)。この目的を達成するために、各試験片の中央に1000μm間隔で六つのマークをつけた。プロファイル測定の長さは250μmの間で実行し、0.69μmごとにデータ収集を行う。試験後、粘着テープを外し、サンプルをもう一度分析した。このようにして、腐食表面の平均深さを特定のソフトウェア(Mahr Perthometer Concept 7.0, Mahr, Gottingen, Germany)を用いて基準表面プロファイルに対して算出した。
象牙質の喪失を各群について算出し(平均±標準偏差)、スチューデントt検定、続いて多重比較のボンフェロ−ニt検定によって統計的に分析した(Statistica 6.0, Statsoft, Tulsa, USA)。
群A〜Eにおける平均象牙質喪失を図6に示す。
対照群(A)における象牙質喪失は9.6μm±1.0であった。試験溶液(B)は、唯一、腐食に対する保護効果を示したものである(7.4μm±0.9)。一方、2%オリーブ油エマルジョン(C)、2%トリメチルグリシン溶液(D)、および1%キシリトール溶液(E)の適用では象牙質に対する保護効果を示さなかった。
Claims (13)
- オリーブ油、トリメチルグリシン、およびキシリトールを含んでなる、口腔乾燥症治療用組成物。
- 0.1〜4重量%のオリーブ油を含んでなる、請求項1に記載の組成物。
- 0.2〜3重量%のオリーブ油を含んでなる、請求項2に記載の組成物。
- 2重量%のオリーブ油を含んでなる、請求項3に記載の組成物。
- 0.1〜6重量%のトリメチルグリシンを含んでなる、請求項1に記載の組成物。
- 4重量%のトリメチルグリシンを含んでなる、請求項5に記載の組成物。
- 1〜50重量%のキシリトールを含んでなる、請求項1に記載の組成物。
- 5〜30重量%のキシリトールを含んでなる、請求項7に記載の組成物。
- 10重量%のキシリトールを含んでなる、請求項8に記載の組成物。
- 2重量%のオリーブ油、4重量%のトリメチルグリシン、および10重量%のキシリトールを含んでなる、請求項1に記載の組成物。
- 2重量%のオリーブ油、2重量%のトリメチルグリシン、および1重量%のキシリトールを含んでなる、請求項1に記載の組成物。
- 再石灰化剤、粘度調整剤、保湿剤、防腐剤、着色剤、緩衝化剤、甘味料、タンパク質分解酵素、乳化剤、研磨剤、精油、瘢痕形成剤、香料、酸化防止剤、植物性および動物性ゼラチン、賦形剤、ならびにその混合物からなる群から選択される一以上の成分を含んでなる、請求項1に記載の組成物。
- 練り歯磨き、口内洗浄剤、代用唾液、スプレー、ゲル、チューインガム、サッカブルカプセル、サッカブルトローチ、口蓋シート、錠剤、菓子、含浸口腔スワブ、含浸口腔ガーゼ、サッカブル単回投与型凍結溶液として処方される、先行する請求項のいずれか一項に記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200700464A ES2304103B1 (es) | 2007-02-22 | 2007-02-22 | Composicion para tratamiento de la xerostomia o boca seca. |
PCT/ES2008/000100 WO2008102041A1 (es) | 2007-02-22 | 2008-02-22 | Composicion para tratamiento de la xerostomía o boca seca |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010519279A true JP2010519279A (ja) | 2010-06-03 |
Family
ID=39708038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009550731A Pending JP2010519279A (ja) | 2007-02-22 | 2008-02-22 | 口腔乾燥症またはドライマウスの治療用組成物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8540970B2 (ja) |
EP (1) | EP2119477B1 (ja) |
JP (1) | JP2010519279A (ja) |
CN (1) | CN101678217B (ja) |
BR (1) | BRPI0807268B1 (ja) |
CA (1) | CA2677854C (ja) |
ES (2) | ES2304103B1 (ja) |
PL (1) | PL2119477T3 (ja) |
PT (1) | PT2119477T (ja) |
TR (1) | TR201809495T4 (ja) |
WO (1) | WO2008102041A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013194025A (ja) * | 2012-03-22 | 2013-09-30 | Sunstar Inc | 液体口腔用組成物 |
JP2014189524A (ja) * | 2013-03-27 | 2014-10-06 | Lion Corp | 口腔用組成物 |
JP2016510308A (ja) * | 2012-12-18 | 2016-04-07 | サンスター スイス エスエー | 口内乾燥症候緩和用及び口内炎処置用の口腔局所用組成物 |
JP2019073452A (ja) * | 2017-10-12 | 2019-05-16 | サンスター株式会社 | 口腔用組成物 |
JP2020529475A (ja) * | 2017-07-31 | 2020-10-08 | ムコサ イノバティオンズ, エセ エレMucosa Innovations, S.L. | 腫瘍処置誘導性の経口胃腸粘膜炎の予防および/または処置における使用のための組成物 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0822251A2 (pt) * | 2008-05-06 | 2015-06-23 | Inst De Investigación En Ortodoncia S L | Composição ativadora do movimento dos dentes |
US8475358B2 (en) * | 2009-07-20 | 2013-07-02 | Jessica Scala | Sexual enhancement lubrication powder |
JP2011026269A (ja) * | 2009-07-28 | 2011-02-10 | Wakodo Co Ltd | 口腔用清拭材 |
MX338801B (es) | 2011-05-16 | 2016-05-02 | Colgate Palmolive Co | Composiciones de cuidado oral. |
AR089518A1 (es) * | 2012-12-27 | 2014-08-27 | Vega Villavicencio Parsival | Costra artificial porosa semipermeable |
SG10201707532WA (en) * | 2013-03-14 | 2017-10-30 | 3 In 1 Dental Pllc | Compositions For Treatment Of Xerostomia And For Tooth Treatment |
US10918589B2 (en) | 2013-03-15 | 2021-02-16 | John Robert Goepfert | Personal-lubricating material and method for lubricant manufacture |
US10363278B2 (en) | 2014-06-15 | 2019-07-30 | Amnio Technology Llc | Frozen therapeutic dose and package |
BR112018010091A2 (pt) | 2015-11-19 | 2019-02-05 | Fantarella & Harewood LLC | colutório não alcoólico e método para inibir o crescimento de células de bactérias na boca |
BR112018075689A2 (pt) * | 2016-06-13 | 2019-04-02 | Meharry Medical College | modulação da via da óxido nítrico sintase para saúde bucal |
EP3506873B1 (en) | 2016-09-22 | 2021-11-03 | Colgate-Palmolive Company | Personal care gel and method |
NL2017656B1 (nl) * | 2016-10-21 | 2018-04-30 | Johan Wagenaar Louis | Samenstelling voor slijmvliesherstel |
AU2018372136B2 (en) | 2017-11-21 | 2022-01-27 | Solventum Intellectual Properties Company | Oral plant-based-oil-in-water emulsions and methods of use |
AU2018392886B2 (en) | 2017-12-20 | 2021-12-23 | Solventum Intellectual Properties Company | Oral compositions and methods of use |
EP3727326A2 (en) | 2017-12-20 | 2020-10-28 | 3M Innovative Properties Company | Oral compositions and methods of use |
EP3603626A1 (en) | 2018-07-31 | 2020-02-05 | Mucosa Innovations, S.L. | Composition for use in the prevention and/or treatment of the genitourinary mucosa |
MX2022010628A (es) | 2020-02-28 | 2022-11-30 | Mucosa Innovations S L | Composicion para la prevencion y tratamiento de la disbiosis. |
CN114504646B (zh) * | 2022-02-18 | 2022-11-04 | 深圳南粤药业有限公司 | 一种含粘蛋白的人工唾液组合物及其制备方法与应用 |
WO2023196667A1 (en) * | 2022-04-08 | 2023-10-12 | LIVIONEX, Inc. | Novel oral care formulations for treatment of xerostomia |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2156569A1 (es) * | 1999-10-05 | 2001-06-16 | Biocosmetics Sl | Empleo del aceite de oliva en la elaboracion de un producto para higiene oral para la eliminacion o reduccion de la placa bacteriana y/o bacterias presentes en la cavidad bucal. |
JP2004511506A (ja) * | 2000-10-16 | 2004-04-15 | バイオコスメティックス・ソシエダッド・リミターダ | 口腔内のバクテリアによるプラークおよび/またはバクテリアを除去または低減するための口内衛生製品の調製におけるオリーブオイルの用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997654A (en) * | 1989-08-14 | 1991-03-05 | Warner-Lambert Company | Method for increasing salivation for xerostomia patients |
CH678601A5 (ja) * | 1989-08-22 | 1991-10-15 | Otto Luft Klimatech Gmbh | |
US5156845A (en) * | 1990-05-04 | 1992-10-20 | Colgate-Palmolive Company | Dry mouth lozenge |
FI106923B (fi) | 1997-01-03 | 2001-05-15 | Cultor Ltd Finnsugar Bioproduc | Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa |
IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
ES2134743B1 (es) * | 1998-02-06 | 2000-05-01 | Biocosmetics Sl | Composicion para el tratamiento de la halitosis. |
ES2150373B1 (es) * | 1998-07-21 | 2001-11-16 | Biocosmetics Sl | Capsulas de gelatina blanda que contienen aceite de oliva. |
US20020131990A1 (en) * | 2000-11-30 | 2002-09-19 | Barkalow David G. | Pullulan free edible film compositions and methods of making the same |
ES2186569B1 (es) * | 2001-09-28 | 2004-09-16 | Lacer, S.A. | Composiciones para el alivio de la xerostomia y el tratamiento de los trastornos asociados con la misma. |
AT414095B (de) | 2003-03-11 | 2006-09-15 | Gebro Pharma Gmbh | Sialagogum auf basis einer lebensmittelsäure |
FR2871700B1 (fr) * | 2004-06-17 | 2006-11-17 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, et une phase huileuse |
-
2007
- 2007-02-22 ES ES200700464A patent/ES2304103B1/es active Active
-
2008
- 2008-02-22 PL PL08736702T patent/PL2119477T3/pl unknown
- 2008-02-22 TR TR2018/09495T patent/TR201809495T4/tr unknown
- 2008-02-22 JP JP2009550731A patent/JP2010519279A/ja active Pending
- 2008-02-22 PT PT87367025T patent/PT2119477T/pt unknown
- 2008-02-22 WO PCT/ES2008/000100 patent/WO2008102041A1/es active Application Filing
- 2008-02-22 US US12/036,005 patent/US8540970B2/en active Active
- 2008-02-22 EP EP08736702.5A patent/EP2119477B1/en active Active
- 2008-02-22 BR BRPI0807268A patent/BRPI0807268B1/pt active IP Right Grant
- 2008-02-22 US US12/527,753 patent/US20100098791A1/en not_active Abandoned
- 2008-02-22 ES ES08736702.5T patent/ES2675949T3/es active Active
- 2008-02-22 CN CN2008800057182A patent/CN101678217B/zh active Active
- 2008-02-22 CA CA2677854A patent/CA2677854C/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2156569A1 (es) * | 1999-10-05 | 2001-06-16 | Biocosmetics Sl | Empleo del aceite de oliva en la elaboracion de un producto para higiene oral para la eliminacion o reduccion de la placa bacteriana y/o bacterias presentes en la cavidad bucal. |
JP2004511506A (ja) * | 2000-10-16 | 2004-04-15 | バイオコスメティックス・ソシエダッド・リミターダ | 口腔内のバクテリアによるプラークおよび/またはバクテリアを除去または低減するための口内衛生製品の調製におけるオリーブオイルの用途 |
US7074391B1 (en) * | 2000-10-16 | 2006-07-11 | Biocosmetics, S.L. | Use of olive oil in the preparation of a product for oral hygiene for eliminating or reducing bacterial plaque and/or bacteria in the mouth |
Non-Patent Citations (5)
Title |
---|
JPN6013015883; 日本ヘルスケア歯科研究会誌 4, 2002, pp.45-55 * |
JPN6013015885; SOEFW Journal 129(11), 2003, pp.24-30 * |
JPN6013015888; Manufacturing Chemist 70(10), 1999, pp.12-15 * |
JPN6013015891; 埼玉県立がんセンター看護部看護研究集録 29, 2005, pp.51-54 * |
JPN6013015893; Dental Diamond 31(5), 2006, pp.151-154 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013194025A (ja) * | 2012-03-22 | 2013-09-30 | Sunstar Inc | 液体口腔用組成物 |
JP2016510308A (ja) * | 2012-12-18 | 2016-04-07 | サンスター スイス エスエー | 口内乾燥症候緩和用及び口内炎処置用の口腔局所用組成物 |
JP2014189524A (ja) * | 2013-03-27 | 2014-10-06 | Lion Corp | 口腔用組成物 |
JP2020529475A (ja) * | 2017-07-31 | 2020-10-08 | ムコサ イノバティオンズ, エセ エレMucosa Innovations, S.L. | 腫瘍処置誘導性の経口胃腸粘膜炎の予防および/または処置における使用のための組成物 |
JP7096332B2 (ja) | 2017-07-31 | 2022-07-05 | ムコサ イノバティオンズ,エセ エレ | 腫瘍処置誘導性の経口胃腸粘膜炎の予防および/または処置における使用のための組成物 |
JP2019073452A (ja) * | 2017-10-12 | 2019-05-16 | サンスター株式会社 | 口腔用組成物 |
JP7368931B2 (ja) | 2017-10-12 | 2023-10-25 | サンスター株式会社 | 口腔用組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN101678217A (zh) | 2010-03-24 |
EP2119477A1 (en) | 2009-11-18 |
BRPI0807268A2 (pt) | 2014-05-06 |
CN101678217B (zh) | 2013-12-25 |
ES2304103B1 (es) | 2009-08-07 |
US20080241080A1 (en) | 2008-10-02 |
ES2675949T3 (es) | 2018-07-13 |
US20100098791A1 (en) | 2010-04-22 |
CA2677854A1 (en) | 2008-08-28 |
ES2304103A1 (es) | 2008-09-01 |
PL2119477T3 (pl) | 2018-11-30 |
US8540970B2 (en) | 2013-09-24 |
EP2119477B1 (en) | 2018-04-04 |
PT2119477T (pt) | 2018-07-05 |
WO2008102041A1 (es) | 2008-08-28 |
EP2119477A4 (en) | 2012-02-29 |
CA2677854C (en) | 2015-10-27 |
BRPI0807268B1 (pt) | 2016-10-11 |
TR201809495T4 (tr) | 2018-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101678217B (zh) | 用于治疗口干燥症或口干的组合物 | |
Singh et al. | Oral implications of polypharmacy in the elderly | |
Han et al. | Dry mouth: a critical topic for older adult patients | |
Szöke et al. | Effect of after-meal sucrose-free gum-chewing on clinical caries | |
Boneta et al. | Efficacy in reducing dentine hypersensitivity of a regimen using a toothpaste containing 8% arginine and calcium carbonate, a mouthwash containing 0.8% arginine, pyrophosphate and PVM/MA copolymer and a toothbrush compared to potassium and negative control regimens: an eight-week randomized clinical trial | |
JP2009517382A (ja) | 口腔ケア用の治療及び予防組成物 | |
BR112020002106B1 (pt) | Composição em gel, método de preparo e uso da mesma | |
Hu et al. | Efficacy of a mouthwash containing 0.8% arginine, PVM/MA copolymer, pyrophosphates, and 0.05% sodium fluoride compared to a negative control mouthwash on dentin hypersensitivity reduction. A randomized clinical trial | |
Chaknis et al. | Assessment of hypersensitivity reduction of a dentifrice containing 0.3% triclosan, 2.0% PVM/MA copolymer, 0.243% NaF and specially-designed silica as compared to a dentifrice containing 0.454% stannous fluoride, sodium hexametaphosphate and zinc lactate and to a dentifrice containing 0.243% NaF on dentin hypersensitivity reduction: An 8-week study. | |
US5571794A (en) | Non-invasive novel method fo cosmetic lip augmentation | |
Smit et al. | Methamphetamine abuse: Oral symptoms and dental treatment needs | |
Hsu et al. | Clinical efficacy of toothpaste containing 8.0% arginine and calcium carbonate for teeth hypersensitivity | |
Kerr et al. | A comparison of the effects of 2 commercially available nonprescription mouthrinses on salivary flow rates and xerostomia. | |
Koc Vural et al. | Clinical performance of composite restorations with resin-modified glass ionomer lining in root surface carious lesions | |
Singla et al. | Papillon Lefevre syndrome: Bridge between dermatologist and dentist | |
Koc Vural et al. | Effect of cavity lining on the restoration of root surface carious lesions: a split-mouth, 5-year randomized controlled clinical trial | |
RU2675257C1 (ru) | Лечебно-профилактическая зубная паста | |
Çolak et al. | A comparison of the fracture resistance of core materials using different types of posts. | |
FR3010634A1 (fr) | Compositions pharmaceutiques a base de tensioactif vegetal pour le traitement de l'hyposialie | |
Milleman et al. | Subjective Assessment of Enamelon® Preventive Treatment Gel in a Self-Reported Dry-Mouth Population. | |
Suresh | Aging and periodontal disease | |
Mehrabi et al. | Xerostomia: Part 2. investigations and management | |
Kanika | Efficacious Evaluation of Aloe Vera Tooth Gel and Commercially Available Tooth Gel on Patients with Gingivitis | |
Fox et al. | Therapy of oral and cutaneous dryness manifestations in Sjögren’s syndrome | |
Kolappan et al. | Xerostomia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130405 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130704 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130711 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131115 |